Several pre-clinical cancer vaccine studies confirmed that CD4+ T cell help is required to induce effective and durable anti-tumor responses,6,7 even to MHC class II-negative tumors,32 and that the presence of tumor-specific help enhances neoantigen-specific CD8+ T cell responses.33 This evidence concerns the gene CD8A and cancer.